Article Highlights
If you currently use the Dexcom G6 and would like to continue using a Dexcom CGM, you should be aware of the following timeline and steps:
Timeline:
- Manufacturing of G6 ends July 1, 2026
- Pharmacies may have inventory available for a period after this date, but Dexcom cannot guarantee supply beyond July 2026
- Dexcom will provide additional transition resources to patients and healthcare providers in early 2026
Action steps:
- Contact your healthcare provider in the coming months to obtain a prescription for Dexcom G7
- Having an updated G7 prescription will ensure your insurance coverage can be properly processed at the pharmacy
- Begin familiarizing yourself with the G7 system and its features
For more information on this announcement, visit Dexcom's official announcement.
Endor will continue to carry both Dexcom G6 sensors and transmitters to support our customers through this transition period. However, we advise being mindful of the July 2026 manufacturing timeline and encourage you to explore the Dexcom G7 system as you plan for your ongoing CGM needs.
Our team is here to help answer questions about both the G6 and G7 systems, and we can assist you in understanding the differences between the two platforms to ensure a smooth transition when you're ready to make the switch.
Dexcom states the phase-out is part of their efforts around sustainability and streamlining their product portfolio. By focusing on a single CGM platform, the company aims to deliver the best possible experience for users while continuing to innovate.
The Dexcom G7 builds on the G6's foundation with several improvements:
- Enhanced accuracy in glucose readings
- Smaller and more discreet sensor design
- Simplified app experience with a more streamlined interface
- Faster warm-up time (30 minutes vs. 2 hours for G6)
The Dexcom G6, introduced in Canada in 2019, marked a major advancement in diabetes management by offering factory-calibrated continuous glucose monitoring (CGM) that does not require routine fingerstick calibrations when used with the sensor code. It delivers real-time glucose readings and customizable alerts to support day-to-day treatment decisions, while still allowing optional manual calibration if needed.
The Dexcom G7, approved by Health Canada in 2023, builds on this technology with a significantly smaller, all-in-one sensor–transmitter design that is more comfortable and discreet. Like the G6, the G7 is factory-calibrated and does not require fingersticks for normal use, though users may optionally enter a blood-glucose value if they want to adjust sensor accuracy.
The Dexcom G7 is covered by most private insurers and various provincial programs across Canada, with broader coverage availability than the G6. However, coverage specifics vary by province and insurance provider.
If you have coverage for Dexcom G6, you'll need to work with your healthcare provider to update your prescription to Dexcom G7. Contact your insurance provider to confirm your G7 coverage details and any authorization requirements that may apply.
Dexcom has stated they will provide additional details and resources in early 2026 to support a smooth transition for all users. In the meantime:
- Continue using your Dexcom G6 as prescribed
- Discuss the transition with your healthcare team at your next appointment
- Monitor communications from Dexcom for transition resources and support
- Contact your insurance provider to understand your G7 coverage
If you have questions about the transition or need support, reach out to your healthcare provider or contact Dexcom Canada directly.
For more information:
- Dexcom Canada: 1-888-738-3646
- Website: www.dexcom.com/en-ca
